Global Growth Hormone Deficiency Therapy Market Size By Type (Parenteral, Transdermal), By Application (Hospitals, Drugstores), By Region, And Segment Forecasts, 2023 to 2032

The Global Growth Hormone Deficiency (GHD) Therapy Market was valued at USD 4.2 billion in 2023 and is projected to reach USD 7.5 billion by 2031, expanding at a CAGR of 7.3% during the forecast period from 2023 to 2031. The market's growth is driven by rising incidences of growth hormone disorders, increased awareness of early diagnosis and treatment, and advancements in recombinant DNA technology. Increasing regulatory approvals for novel therapies and expanding healthcare access in emerging markets are also fueling demand for GHD treatments.

Drivers:

1. Rising Incidence of Growth Hormone Deficiency:

The growing number of children and adults diagnosed with GHD due to genetic, traumatic, or idiopathic factors is propelling demand for effective therapy options. Early diagnosis and increasing availability of testing are facilitating timely treatment initiation.

2. Advancements in Recombinant Human Growth Hormone (rhGH) Therapy:

The development of long-acting growth hormones and needle-free delivery systems enhances patient adherence, contributing to the market's upward trajectory.

3. Expanding Access to Healthcare in Developing Regions:

Governments and private players are investing in healthcare infrastructure and raising awareness about pediatric endocrinology, leading to better access and higher treatment adoption.

Restraints:

1. High Cost of Treatment:

The long-term cost of growth hormone therapy, especially recombinant versions, remains a significant hurdle for low-income populations and underfunded healthcare systems.

2. Strict Regulatory Frameworks:

Complex approval processes and stringent safety evaluations can delay the commercialization of new therapies, limiting innovation pace.

Opportunity:

1. Emergence of Biosimilars and Long-Acting Formulations:

The expiration of patents for key biologics is opening the door for biosimilars, which offer cost-effective treatment options. Simultaneously, the growing adoption of once-weekly or monthly formulations promises better compliance and broader market penetration.

2. Growth in Pediatric and Adult Treatment Populations:

Awareness campaigns and expanded screening protocols are increasing diagnoses not only in children but also in adults with adult-onset GHD, significantly enlarging the target patient base.

Market by System Type Insights:

Based on therapy type, the recombinant human growth hormone (rhGH) segment held the largest market share in 2023. Its effectiveness in both pediatric and adult patients and wide regulatory acceptance contribute to its dominance. Meanwhile, the long-acting GH formulations segment is projected to grow at the fastest rate due to enhanced convenience and improved adherence outcomes.

Market by End-use Insights:

By end-use, pediatric clinics and hospitals were the leading segment in 2023, owing to the early age of onset for most GHD cases. The adult endocrinology centers segment is expected to register substantial growth during the forecast period, driven by increasing awareness of adult GHD and a rise in diagnosis rates among elderly populations.

Market by Regional Insights:

North America dominated the global GHD therapy market in 2023 due to advanced healthcare systems, high diagnosis rates, and the strong presence of key pharmaceutical players. Asia-Pacific is expected to witness the highest CAGR through 2031, supported by growing healthcare investments, urbanization, and government support for rare disease management in countries such as China and India.

Competitive Scenario:

Leading companies in the GHD therapy market include Pfizer Inc., Merck KGaA, Novo Nordisk A/S, Eli Lilly and Company, Ferring Pharmaceuticals, Sandoz (a Novartis division), Genentech, Ipsen, LG Chem, and Teva Pharmaceuticals. These firms are emphasizing R&D investment, strategic alliances, and global expansion.

In 2023, Novo Nordisk launched its long-acting growth hormone therapy “Sogroya” in multiple markets, streamlining weekly administration.

Pfizer and OPKO Health received extended FDA approval for their long-acting GHD drug “Ngenla” in 2022.

Sandoz accelerated its biosimilar pipeline in 2024, targeting cost-sensitive markets in Latin America and Southeast Asia.

Scope of Work – Global Growth Hormone Deficiency Therapy Market

Key Market Developments:

2023: Novo Nordisk’s Sogroya launched in Japan and Australia, expanding access to long-acting GH therapy.

2022: FDA approved Pfizer/OPKO’s once-weekly Ngenla, marking a pivotal innovation in the treatment space.

2024: Sandoz and LG Chem announced collaboration to co-develop a new biosimilar growth hormone targeting Asia-Pacific markets.

FAQs:

1) What is the current market size of the Global Growth Hormone Deficiency Therapy Market?

The market was valued at USD 4.2 billion in 2023.

2) What is the major growth driver of the Global Growth Hormone Deficiency Therapy Market?

Rising incidence of GHD, coupled with innovations in long-acting hormone therapy and improved global healthcare access.

3) Which is the largest region during the forecast period in the Global Growth Hormone Deficiency Therapy Market?

North America held the largest market share in 2023, while Asia-Pacific is expected to grow the fastest.

4) Which segment accounted for the largest market share in Global Growth Hormone Deficiency Therapy Market?

The recombinant human growth hormone (rhGH) therapy segment dominated the market in 2023.

5) Who are the key market players in the Global Growth Hormone Deficiency Therapy Market?

Pfizer, Merck KGaA, Novo Nordisk, Eli Lilly, Ferring Pharmaceuticals, Sandoz, Genentech, Ipsen, LG Chem, and Teva Pharmaceuticals.